Effect of dopamine agonists on fatigue and somnolence in Parkinson's disease

Dopamine agonists are becoming increasingly important in the treatment of early and advanced symptoms of Parkinson disease (PD). Although dopamine agonists are known to increase somnolence, their effect on fatigue and the relationship between fatigue and somnolence have not been investigated thoroug...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Movement disorders Ročník 21; číslo 8; s. 1257 - 1261
Hlavní autoři:	Oved, Daniel, Ziv, Ilan, Treves, Therese A, Paleacu, Diana, Melamed, Eldad, Djaldetti, Ruth
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.08.2006 Wiley
Témata:	Aged Biological and medical sciences Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Depression Dopamine Agents - pharmacology dopamine agonists Fatigue Female Functional Laterality Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy Humans Male Medical sciences Middle Aged Nervous system (semeiology, syndromes) Neurology Parkinson Disease - physiopathology Parkinson Disease - psychology Parkinson's disease Parkinsons Disease Psychological Tests Sleep - drug effects somnolence somnolence, Parkinson's disease Surveys and Questionnaires Somnolence Nervous system diseases Parkinson's disease Central nervous system disease Dopamine agonist Parkinson disease Fatigue Degenerative disease dopamine agonists; fatigue; somnolence Cerebral disorder Extrapyramidal syndrome
ISSN:	0885-3185, 1531-8257
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Dopamine agonists are becoming increasingly important in the treatment of early and advanced symptoms of Parkinson disease (PD). Although dopamine agonists are known to increase somnolence, their effect on fatigue and the relationship between fatigue and somnolence have not been investigated thoroughly. The objective of this study is to quantitatively measure fatigue in patients with PD treated with dopamine agonists and to correlate fatigue with somnolence. Fifteen patients with PD (mean age, 60.6 ± 9.7 years; mean disease duration, 4.1 ± 1.9 years) underwent a continuous (30‐second) motor task using four muscle groups before and after 3 months of treatment with dopamine agonists. A fatigue index, defined as the decay of maximal force during continuous exercise, was calculated. Findings were compared with 15 healthy, age‐matched control subjects. Patients also completed the Multidimensional Fatigue Inventory (MFI), the Epworth Sleepiness Scale (ESS), and the Hamilton Depression Scale at the same time points. Mean fatigue index (FI) before treatment was significantly higher in PD patients than controls (31.37% ± 3.81% vs. 23.39% ± 3.03%, P < 0.001). There was no significant between‐group difference after 3 months of treatment. There was no difference in FI of the more affected side before and after treatment (33.33% ± 6.18% vs. 34.08% ± 5.43%, P > 0.1). No significant change in MFI scores were noted after treatment, although scores on the ESS increased significantly (6.6 ± 2.63 vs. 11.7 ± 5.16; P < 0.05). Fatigue is prevalent in patients with PD but is not influenced by dopamine agonists. Somnolence cannot be attributed to the increase in fatigability and apparently involves a different mechanism. © 2006 Movement Disorder Society
Bibliografie:	ArticleID:MDS20929 National Parkinson's Foundation, USA Alan and Norma Aufzien Chair for Research in Parkinson's Disease Sackler School of Medicine, Tel Aviv University ark:/67375/WNG-L9DLDKTN-T istex:3D2024886689A4FFEFC2A1653A88BC5959151454 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0885-3185 1531-8257
DOI:	10.1002/mds.20929